Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2

Journal of Molecular Medicine

Volumn 90, Issue 3, 2012, Pages 309-319

  Min, Kyoung Jin ^a   Jang, Ji Hoon ^a   Lee, Jung Tae ^a   Choi, Kyeong Sook ^a,b   Kwon, Taeg Kyu ^a  

^a Keimyung University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Bcl 2; C FLIP(L); Death receptor; RU486; TRAIL

Indexed keywords

DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; GLUCOCORTICOID RECEPTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MIFEPRISTONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIZATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

APOPTOSIS; CARCINOMA, RENAL CELL; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE; DOWN-REGULATION; HT29 CELLS; HUMANS; MESANGIAL CELLS; MIFEPRISTONE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, GLUCOCORTICOID; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR CHOP; UP-REGULATION;

EID: 84862532891     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0821-8     Document Type: Article

References (41)

1. Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE (1982) The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C R Seances Acad Sci III 294:933-938
2. Robbins A, Spitz IM (1996) Mifepristone: clinical pharmacology. Clin Obstet Gynecol 39:436-450
3. Gagne D, Pons M, Philibert D (1985) RU 38486: a potent antiglucocorticoid in vitro and in vivo. J Steroid Biochem 23:247-251
4. Jung-Testas I, Baulieu EE (1983) Inhibition of glucocorticosteroid action in cultured L-929 mouse fibroblasts by RU 486, a new antiglucocorticosteroid of high affinity for the glucocorticosteroid receptor. Exp Cell Res 147:177-182
5. Bardon S, Vignon F, Chalbos D, Rochefort H (1985) RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab 60:692-697
6. Olson JJ, Beck DW, Schlechte JA, Loh PM (1987) Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg 66:584-587
7. Rose FV, Barnea ER (1996) Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 12:999-1003
8. Sartor O, Figg WD (1996) Mifepristone: antineoplastic studies. Clin Obstet Gynecol 39:498-505
9. Kamradt MC, Mohideen N, Vaughan AT (2000) RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol 77:177-182
10. Lecureur V, Fardel O, Guillouzo A (1994) The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 355:187-191
11. Eid MA, Lewis RW, Kumar MV (2002) Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). Mol Cancer Ther 1:831-840
12. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682
13. Kataoka T (2005) The caspase-8 modulator c-FLIP. Crit Rev Immunol 25:31-58
14. Safa AR, Day TW, Wu CH (2008) Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets 8:37-46
15. Jin Z, McDonald ER 3rd, Dicker DT, El-Deiry WS (2004) Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279:35829-35839
16. Kelly MM, Hoel BD, Voelkel-Johnson C (2002) Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 1:520-527
17. Ng CP, Zisman A, Bonavida B (2002) Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 53:286-299
18. Walczak H, Bouchon A, Stahl H, Krammer PH (2000) Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2-or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res 60:3051-3057
19. Zhang Y, Zhang B (2008) TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6:1861-1871
20. Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G, Darai E (2006) Effects of progesterone and antiprogestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep 15:743-748
21. Zhang H, Lu JJ, Gao QZ, Zhang J (2006) Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro. Zhonghua Wai Ke Za Zhi 44:382-385
22. Ruiz de Almodovar C, Ruiz-Ruiz C, Munoz-Pinedo C, Robledo G, Lopez-Rivas A (2001) The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicininduced apoptosis is dependent on Bc1-2 protein levels. Oncogene 20:7128-7133
23. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111-113
24. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA et al (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386-5397
25. Yamaguchi H, Wang HG (2004) CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279:45495-45502
26. Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T (2005) Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 65:5662-5667
27. Petrella A, Ercolino SF, Festa M, Gentilella A, Tosco A, Conzen SD, Parente L (2006) Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. Eur J Cancer 42:3287-3293
28. Mahajan DK, London SN (1997) Mifepristone (RU486): a review. Fertil Steril 68:967-976
29. Bonelli RM (1992) Mifepristone (RU 486). Diskussionsforum Med Ethik XXXVIII-XLIII
30. Goldberg JR, Plescia MG, Anastasio GD (1998) Mifepristone (RU 486): current knowledge and future prospects. Arch Fam Med 7:219-222
31. Haak HR, de Keizer RJ, Hagenouw-Taal JC, van Seters AP, Vielvoye GJ, van Dulken H (1990) Successful mifepristone treatment of recurrent, inoperable meningioma. Lancet 336:124-125
32. Jurado R, Lopez-Flores A, Alvarez A, Garcia-Lopez P (2009) Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Oncol Rep 22:1237-1245
33. Huang J, Zhang Y, Huang Y, Zhang X, Xiao J (2010) Reversal effect of mifepristone on adriamycin resistance in human breast cancer cell line MCF-7/ADM in vitro and in vivo. Zhong Nan Da Xue Xue Bao Yi Xue Ban 35:576-583
34. Dioufa N, Kassi E, Papavassiliou AG, Kiaris H (2010) Atypical induction of the unfolded protein response by mifepristone. Endocrine 38:167-173
35. Lee JT, Lee TJ, Park JW, Kwon TK (2009) Se-methylselenocysteine sensitized TRAIL-mediated apoptosis via down-regulation of Bcl-2 expression. Int J Oncol 34:1455-1460
36. Um HJ, Oh JH, Kim YN, Choi YH, Kim SH, Park JW, Kwon TK (2010) The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. Chem Biol Interact 186:36-42
37. Aurora AB, Biyashev D, Mirochnik Y, Zaichuk TA, Sanchez-Martinez C, Renault MA, Losordo D, Volpert OV (2010) NFkappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. Blood 116:475-484
38. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J (2001) NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 21:5299-5305
39. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF (2007) c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 67:9425-9434
40. Fukazawa T, Fujiwara T, Uno F, Teraishi F, Kadowaki Y, Itoshima T, Takata Y, Kagawa S, Roth JA, Tschopp J et al (2001) Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 20:5225-5231
41. Kaunisto A, Kochin V, Asaoka T, Mikhailov A, Poukkula M, Meinander A, Eriksson JE (2009) PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability. Cell Death Differ 16:1215-1226